1093 Stoklara Genel Bakış Bir yatırım holding şirketi olan CSPC Pharmaceutical Group Limited, Çin Halk Cumhuriyeti'nde, diğer Asya bölgelerinde, Kuzey Amerika'da, Avrupa'da ve uluslararası alanda farmasötik ürünlerin araştırılması ve geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Daha fazla detay
Ödüller Risk Analizi Tüm Risk Kontrollerini Gör Düşüncelerinizi, bağlantılarınızı ve şirket anlatımınızı yakalayın
CSPC Pharmaceutical Group Limited Rakipler Fiyat Geçmişi ve Performans
Hisse fiyatlarındaki yükseliş, düşüş ve değişimlerin özeti CSPC Pharmaceutical Group Tarihsel hisse senedi fiyatları Güncel Hisse Fiyatı HK$4.80 52 Haftanın En Yüksek Seviyesi HK$7.83 52 Haftanın En Düşük Seviyesi HK$4.45 Beta 0.64 1 Aylık Değişim -5.70% 3 Aylık Değişim -8.40% 1 Yıllık Değişim -30.13% 3 Yıllık Değişim -41.82% 5 Yıllık Değişim -50.40% Halka arzdan bu yana değişim 26.94%
Son Haberler & Güncellemeler CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
Third quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.13 in 3Q 2023) Nov 16
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06
Investor sentiment deteriorates as stock falls 15% Nov 01
Upcoming dividend of HK$0.16 per share Oct 24 Daha fazla güncelleme görün CSPC Pharmaceutical Group Limited Announces SYS6005 (Antibody-Drug Conjugate) Obtains Clinical Trial Approval
CSPC Pharmaceutical Group Limited Announces Board Changes Dec 06
Third quarter 2024 earnings released: EPS: CN¥0.065 (vs CN¥0.13 in 3Q 2023) Nov 16
CSPC Pharmaceutical Group Limited to Report Nine Months, 2024 Results on Nov 15, 2024 Nov 06
Investor sentiment deteriorates as stock falls 15% Nov 01
Upcoming dividend of HK$0.16 per share Oct 24 CSPC Pharmaceutical Group Limited Announces Omalizumab for Injection Obtains Marketing Approval from NMPA
Investor sentiment improves as stock rises 16% Sep 26
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023) Sep 21
CSPC Pharmaceutical Group Limited Announces Valsartan Levoamlodipine Maleate Tablets Obtains Clinical Trial Approval Sep 20 CSPC Pharmaceutical Group Limited (SEHK:1093) announces an Equity Buyback for HKD 5,000 million worth of its shares. Sep 19
Executive Chairman recently bought HK$4.6m worth of stock Sep 10 CSPC Pharmaceutical Group Limited Announces Aprepitant Injection Obtains Drug Registration Approval
Investor sentiment deteriorates as stock falls 17% Aug 28
Executive Chairman recently bought HK$6.7m worth of stock Aug 24
Second quarter 2024 earnings released: EPS: CN¥0.12 (vs CN¥0.13 in 2Q 2023) Aug 22
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2024, Payable on 20 November 2024 Aug 21
CSPC Pharmaceutical Group Limited to Report First Half, 2024 Results on Aug 21, 2024 Aug 09
CSPC Pharmaceutical Group Limited Obtains Approval from the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jul 11 CSPC Pharmaceutical Group Limited Announces Enlonstobart Injection Obtains Conditional Marketing Approval
CSPC Pharmaceutical Group Limited Obtains Approval from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Jun 25 CSPC Pharmaceutical Group Limited Approves Final Dividend for the Year Ended December 31, 2023
First quarter 2024 earnings released: EPS: CN¥0.14 (vs CN¥0.12 in 1Q 2023) May 28
Upcoming dividend of HK$0.14 per share May 24
CSPC Pharmaceutical Group Limited Announces Recombinant Fully Human Anti-bKlotho Monoclonal Antibody Drug (JMT202) Obtains Approval from National Medical Products Administration of the People's Republic of China May 18
CSPC Pharmaceutical Group Limited to Report Q1, 2024 Results on May 27, 2024 May 16
Cspc Pharmaceutical Group Limited Announces That the Peramivir Injection (15Ml:0.15G) (The "Product") Developed by the Group Has Obtained Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China, and Is Deemed to Have Passed the Consistency Evaluation of Quality and Efficacy for Generic Drugs May 15
CSPC Pharmaceutical Group Limited Proposes Final Dividend for the Year Ended 31 December 2023 Apr 28
Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022) Apr 27
CSPC Pharmaceutical Group Limited Announces Highly Selective Mat2A Inhibitor (SYH2039) Obtains Clinical Trial Approval in the U.S Apr 27
CSPC Pharmaceutical Group Limited Announces Dapagliflozin Tablets Obtains Drug Registration Approval Mar 23
CSPC Pharmaceutical Group Limited, Annual General Meeting, May 28, 2024 Mar 21
Full year 2023 earnings released: EPS: CN¥0.49 (vs CN¥0.51 in FY 2022) Mar 21
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate SYS6023 Obtains Clinical Trial Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Mar 21
CSPC Pharmaceutical Group Limited Proposes Ordinary Final Cash Dividend for the Year Ended 31 December 2023, Payable on 26 June 2024 Mar 20
CSPC Pharmaceutical Group Limited to Report Fiscal Year 2023 Results on Mar 20, 2024 Mar 09
CSPC Pharmaceutical Group Limited's Bispecific Fusion Protein Drug JMT106 Obtains Clinical Trial Approval from the U.S. Food and Drug Administration Jan 15
CSPC Pharmaceutical Group Limited Announces Submission of New Drug Application for Irinotecan Liposome Injection to U.S. FDA Dec 18
CSPC Pharmaceutical Group Limited Obtains Approval for Dextromethorphan Hydrobromide and Quinidine Sulphate Orally Disintegrating Tablets Dec 12
CSPC Pharmaceutical Group Limited Announces Bivalent Covid-19 MRNA Vaccine (SYS6006.32) Included for Emergency Use in China Dec 02
Third quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 3Q 2022) Dec 01
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 29
CSPC Pharmaceutical Group Limited Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Nov 28
CSPC Pharmaceutical Group Limited to Report Nine Months, 2023 Results on Nov 30, 2023 Nov 21
CSPC Pharmaceutical Group Limited's ALMB-0166 Obtains Approval by the National Medical Products Administration of the People's Republic of China to Conduct Phase II Clinical Trial Evaluating its Efficacy and Safety in Patients with Acute Ischemic Stroke in China Nov 18
Alphamab Oncology and CSPC Pharmaceutical Group Co., Ltd. Jointly Receive Breakthrough Therapy Designation on KN026 by CDE Nov 08
CSPC Pharmaceutical Group Limited Obtains Approval Granted by the National Medical Products Administration of the People's Republic of China Nov 04
CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Oct 31
Investor sentiment improves as stock rises 19% Oct 28
CSPC Pharmaceutical Group Limited Announces NBL-028 for the Treatment of Advanced Tumors Oct 26
CSPC Pharmaceutical Group Limited Announces Biologic License Application Approval for Narlumosbart for Injection (JMT103) by the NMPA Sep 07
Upcoming dividend of HK$0.14 per share at 4.7% yield Aug 31
CSPC Pharmaceutical Group Limited Announces Semaglutide Injection Obtains Clinical Trial Approval Aug 30
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 25
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2023, Payable on 12 October 2023 Aug 24
Second quarter 2023 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2022) Aug 24
CSPC Pharmaceutical Group Limited to Report First Half, 2023 Results on Aug 23, 2023 Aug 12
Cspc Pharmaceutical Group Limited Announces Biologic License Application of Batoclimab (Hbm9161) Jun 30
CSPC Ouyi Pharmaceutical Co., Ltd. Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Jun 27 CSPC Pharmaceutical Group Limited Obtains Clinical Trial Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China
Cspc Pharmaceutical Group Limited Announces That Clinical Trial Application for Cpo301 Jun 09
Elevation Oncology Inc. Together with CSPC Pharmaceutical Group Limited Announce Promising Initial Clinical Data for SYSA1801 (EO-3021) from the Ongoing Phase 1 Dose Escalation and Expansion Study in China Jun 07
Elevation Oncology Highlights First-In-Human Phase 1 Sysa1801 (Eo-3021) Clinical Data to Be Presented by Partner Cspc Pharmaceutical Group Limited At Asco 2023 Jun 06
CSPC Pharmaceutical Group Limited Declares Final Dividend for the Year Ended 31 December 2022 Jun 01
Upcoming dividend of HK$0.11 per share at 3.1% yield May 29
First quarter 2023 earnings released: EPS: CN¥0.12 (vs CN¥0.12 in 1Q 2022) May 27
CSPC Pharmaceutical Group Limited to Report Q1, 2023 Results on May 25, 2023 May 17
Executive Chairman recently bought HK$13m worth of stock Mar 30
Full year 2022 earnings released: EPS: CN¥0.51 (vs CN¥0.47 in FY 2021) Mar 23
CSPC Pharmaceutical Group Limited Announces Highly Selective PRMT5 Inhibitor SYH2045 Obtains Clinical Trial Approval Jan 05
Cspc Pharmaceutical Group Limited Announces ALMB-0166 for the Treatment of Osteoarthritis Obtains Clinical Trial Approval Dec 31
CSPC Pharmaceutical Group Limited Receives Approval for SYH2043 from National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 30
CSPC Pharmaceutical Group Limited Announces NBL-020 for the Treatment of Advanced Solid Tumors Obtains Clinical Trial Approval in the U.S Dec 23
Cspc Pharmaceutical Group Limited Announces That Syh2055 Developed by the Group Has Obtained Approval Granted by the National Medical Products Administration of the People's Republic of China to Conduct Clinical Trials in China Dec 08
CSPC Pharmaceutical Group Limited Announces Antibody-Drug Conjugate CPO204 Obtains Clinical Trial Approval in the U.S Nov 30
Third quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.11 in 3Q 2021) Nov 25
CSPC Pharmaceutical Group Limited's SYHX1901 Tablets Obtains Approval Granted by the National Medical Products Administration Nov 24
CSPC Pharmaceutical Group Limited Announces New Indication Application for Marketing Approval of Mingfule Nov 17
CSPC Pharmaceutical Group Limited to Report Nine Months, 2022 Results on Nov 23, 2022 Nov 12
CSPC Pharmaceutical Group Limited Appoints Li Quan as an Independent Non-Executive Director Nov 09
Investor sentiment improved over the past week Nov 03
CSPC Pharmaceutical Group Limited Announces the Antibody-Drug Conjugate Sys6002 Oct 28
CSPC Pharmaceutical Group Limited Announces TG103 Injection Obtains Clinical Trial Approval for the Treatment of Non-Alcoholic Steatohepatitis Sep 10
Upcoming dividend of HK$0.10 per share Sep 01
CSPC Pharmaceutical Group Limited Declares Interim Dividend for the Six Months Ended 30 June 2022, Payable on 11 October 2022 Aug 25
Second quarter 2022 earnings released: EPS: CN¥0.13 (vs CN¥0.13 in 2Q 2021) Aug 25
CSPC Pharmaceutical Group Limited Announces Completion of Clinical Study of Heterologous Booster Immunization of SARS-CoV-2 mRNA Vaccine Aug 24
Cspc Pharmaceutical Group Limited Announces Selective Ntrk and Ros1 Dual Inhibitor Syhx2009 Obtains Clinical Trial Approval Aug 23
CSPC Pharmaceutical Group Limited Obtains Drug Registration Approval Granted by the National Medical Products Administration of the People's Republic of China Aug 20 Hissedar Getirileri 1093 HK Pharmaceuticals HK Pazar 7D 3.7% 2.0% 2.3% 1Y -30.1% -2.6% 22.4%
Hissedar getirilerinin tamamını görün
Getiri vs. Endüstri: 1093 geçen yıl % -2.6 oranında getiri sağlayan Hong Kong Pharmaceuticals sektörünün gerisinde kaldı.
Getiri vs Piyasa: 1093 geçen yıl % 22.4 oranında getiri sağlayan Hong Kong Piyasasının altında performans gösterdi.
Fiyat Oynaklığı Is 1093's price volatile compared to industry and market? 1093 volatility 1093 Average Weekly Movement 7.2% Pharmaceuticals Industry Average Movement 6.4% Market Average Movement 8.8% 10% most volatile stocks in HK Market 18.5% 10% least volatile stocks in HK Market 4.0%
İstikrarlı Hisse Senedi Fiyatı: 1093 son 3 ayda önemli bir fiyat oynaklığı yaşamadı.
Zaman İçindeki Volatilite: 1093 'nin haftalık oynaklığı ( 7% ) son bir yıldır istikrarlı seyretti.
Şirket Hakkında Bir yatırım holding şirketi olan CSPC Pharmaceutical Group Limited, Çin Halk Cumhuriyeti'nde, diğer Asya bölgelerinde, Kuzey Amerika'da, Avrupa'da ve uluslararası alanda farmasötik ürünlerin araştırılması ve geliştirilmesi, üretimi ve satışı ile ilgilenmektedir. Şirket, Bitmiş İlaçlar, Dökme Ürünler ve Fonksiyonel Gıda ve Diğerleri segmentleri aracılığıyla faaliyet göstermektedir. Akut iskemik inme için NBP yumuşak kapsülleri ve enjeksiyonları; hafif ila orta dereceli hafıza ve zihinsel bozukluğu tedavi etmek için Oulaining kapsülleri ve enjeksiyonları; yetişkin idiyopatik Parkinson hastalığını tedavi etmek için Enxi; lenfoma, multipl miyelom, yumurtalık ve meme kanserleri ve diğer kötü huylu tümörler için Duomeisu; kemoterapinin neden olduğu lökopeni ve enfeksiyonu önlemek için Jinyouli ve meme kanseri için Keaili sağlar.
Daha fazla göster CSPC Pharmaceutical Group Limited Temel Bilgiler Özeti CSPC Pharmaceutical Group'un kazançları ve gelirleri piyasa değeriyle nasıl karşılaştırılır? 1093 temel i̇stati̇sti̇kler Piyasa değeri HK$55.67b Kazançlar(TTM ) HK$5.49b Gelir(TTM ) HK$32.22b
Kazanç ve Gelir En son kazanç raporundan temel karlılık istatistikleri (TTM) 1093 gelir tablosu (TTM ) Gelir CN¥30.27b Gelir Maliyeti CN¥8.90b Brüt Kâr CN¥21.37b Diğer Giderler CN¥16.21b Kazançlar CN¥5.16b
Temettüler
6.6% Mevcut Temettü Verimi
Şirket Analizi ve Finansal Veri Durumu Veri Son Güncelleme (UTC saati) Şirket Analizi 2024/12/24 14:16 Gün Sonu Hisse Fiyatı 2024/12/24 00:00 Kazançlar 2024/09/30 Yıllık Kazançlar 2023/12/31
Veri Kaynakları Şirket analizimizde kullanılan veriler S&P Global Market Intelligence LLC 'den alınmıştır. Bu raporu oluşturmak için analiz modelimizde aşağıdaki veriler kullanılmıştır. Veriler normalize edilmiştir, bu da kaynağın mevcut olmasından kaynaklanan bir gecikmeye neden olabilir.
Paket Veri Zaman Çerçevesi Örnek ABD Kaynağı * Şirket Finansalları 10 yıl Gelir tablosu Nakit akış tablosu Bilanço Analist Konsensüs Tahminleri +3 yıl Finansal tahminler Analist fiyat hedefleri Piyasa Fiyatları 30 yıl Hisse senedi fiyatları Temettüler, Bölünmeler ve Eylemler Sahiplik 10 yıl En büyük hissedarlar İçeriden öğrenenlerin ticareti Yönetim 10 yıl Liderlik ekibi Yönetim Kurulu Önemli Gelişmeler 10 yıl
* ABD menkul kıymetleri için örnek, ABD dışı için eşdeğer düzenleyici formlar ve kaynaklar kullanılır.
Belirtilmediği sürece tüm finansal veriler yıllık bir döneme dayanmaktadır ancak üç ayda bir güncellenmektedir. Bu, İzleyen On İki Ay (TTM) veya Son On İki Ay (LTM) Verileri olarak bilinir. Buradan daha fazla bilgi edinin.
Analiz Modeli ve Kar Tanesi Bu raporu oluşturmak için kullanılan analiz modelinin ayrıntıları Github sayfamızda mevcuttur, ayrıca raporlarımızın nasıl kullanılacağına dair kılavuzlarımız ve Youtube' da eğitimlerimiz bulunmaktadır.
Simply Wall St analiz modelini tasarlayan ve oluşturan dünya standartlarındaki ekip hakkında bilgi edinin.
Endüstri ve Sektör Metrikleri Sektör ve bölüm metriklerimiz Simply Wall St tarafından her 6 saatte bir hesaplanmaktadır, sürecimizin ayrıntıları 'da mevcuttur.
Analist Kaynakları CSPC Pharmaceutical Group Limited 50 Bu analistlerden 27, raporumuzun girdisi olarak kullanılan gelir veya kazanç tahminlerini sunmuştur. Analistlerin gönderimleri gün boyunca güncellenmektedir.
Analist Kurum Wai Chak Yuen BOCI Research Ltd. Sharon Shi BOCI Research Ltd. Ethan Cui BofA Global Research
Göster 47 daha fazla analist 
